Inhibikase Therapeutics names Scott M. Wasserman to board

IKT•2026-11-10

Inhibikase Therapeutics appointed Scott M. Wasserman to its board in October 2026; he is Kailera Therapeutics' chief medical officer and a cardiologist with more than two decades of clinical development and company leadership experience.

1. Board appointment

Inhibikase Therapeutics announced Scott M. Wasserman's appointment to its board in October 2026. Wasserman is Kailera Therapeutics' chief medical officer and a cardiologist with more than two decades of clinical development and company leadership experience.

Inhibikase Therapeutics names Scott M. Wasserman to board

1. Board appointment

Related News

Alzamend Neuro cuts preferred stock financing to $10 million from $25 million in amended agreement

Lincoln National declares quarterly cash dividend of $0.45 per share

Motorola Solutions chairman and CEO Gregory Q. Brown reports sale of $36.39 million in common shares

OneWater Marine extends term loan and floor plan credit facilities to 2029

Peloton Interactive prices upsized $700 million offering of 8.625% senior secured notes due 2032